Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Milton Packer

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Physiology

Chemicals & Drugs

Procedures

Double-Blind Method

Concepts & Ideas

Anatomy

Renin-Angiotensin System

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
19
Massie, Barrie
17
Rouleau, Jean-Lucien
16
Gottlieb, Stephen
15
Krum, Henry
13
Kukin, Marrick
10
Fowler, Michael
9
Burkhoff, Daniel
7
Coats, Andrew
7
Katus, Hugo
7
Mohacsi, Paul
7
Tendera, Michal
6
Roecker, Ellen
6
Moyé, Lemuel
6
Goldsmith, Rochelle
5
Cohn, Jay

Sign-in to see all Coauthors

Publications

TOP 3
Mebazaa Alexandre; Nieminen Markku S; Packer Milton; Cohen-Solal Alain; Kleber Franz X; Pocock Stuart J; Thakkar Roopal; Padley Robert J; Põder Pentti; Kivikko Matti;
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Frazier Camille G; Alexander Karen P; Newby L Kristin; Anderson Susan; Iverson Erik; Packer Milton; Cohn Jay; Goldstein Sidney; Douglas Pamela S
Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials.
Tam S William; Sabolinski Michael L; Worcel Manuel; Packer Milton; Cohn Jay N
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Milton Packer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2007: Mebazaa Alexandre; Nieminen Markku S; Packer Milton; Cohen-Solal Alain; Kleber Franz X; Pocock Stuart J; Thakkar Roopal; Padley Robert J; Põder Pentti; Kivikko Matti;
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
JAMA : the journal of the American Medical Association 2007;297(17):1883-91.
2007: Frazier Camille G; Alexander Karen P; Newby L Kristin; Anderson Susan; Iverson Erik; Packer Milton; Cohn Jay; Goldstein Sidney; Douglas Pamela S
Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials.
Journal of the American College of Cardiology 2007;49(13):1450-8.
2007: Tam S William; Sabolinski Michael L; Worcel Manuel; Packer Milton; Cohn Jay N
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Clinical pharmacokinetics 2007;46(10):885-95.
2006: Packer Milton
Controlled-release carvedilol: a concluding perspective.
The American journal of cardiology 2006;98(7A):67L-69L.
2006: Packer Milton; Lukas Mary Ann; Tenero David M; Baidoo Charlotte A; Greenberg Barry H;
Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
The American journal of cardiology 2006;98(7A):39L-45L.
2006: Packer Milton; Abraham William T; Mehra Mandeep R; Yancy Clyde W; Lawless Christine E; Mitchell Judith E; Smart Frank W; Bijou Rachel; O'Connor Christopher M; Massie Barry M; Pina Ileana L; Greenberg Barry H; Young James B; Fishbein Daniel P; Hauptman Paul J; Bourge Robert C; Strobeck John E; Murali Srinvivas; Schocken Douglas; Teerlink John R; Levy Wayne C; Trupp Robin J; Silver Marc A;
Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure.
Journal of the American College of Cardiology 2006;47(11):2245-52.
2006: Levy Wayne C; Mozaffarian Dariush; Linker David T; Sutradhar Santosh C; Anker Stefan D; Cropp Anne B; Anand Inder; Maggioni Aldo; Burton Paul; Sullivan Mark D; Pitt Bertram; Poole-Wilson Philip A; Mann Douglas L; Packer Milton
The Seattle Heart Failure Model: prediction of survival in heart failure.
Circulation 2006;113(11):1424-33.
2006: Krum Henry; Mohacsi Paul; Katus Hugo A; Tendera Michael; Rouleau Jean-Lucien; Fowler Michael B; Coats Andrew J; Roecker Ellen B; Packer Milton;
Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
American heart journal 2006;151(1):55-61.
2005: Krum Henry; Haas Steven Joseph; Eichhorn Eric; Ghali Jalal; Gilbert Edward; Lechat Philippe; Packer Milton; Roecker Ellen; Verkenne Patricia; Wedel Hans; Wikstrand John
Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.
European heart journal 2005;26(20):2154-8.
2005: Pattingre Sophie; Tassa Amina; Qu Xueping; Garuti Rita; Liang Xiao Huan; Mizushima Noboru; Packer Milton; Schneider Michael D; Levine Beth
Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy.
Cell 2005;122(6):927-39.
2005: Solomon Scott D; Skali Hicham; Bourgoun Mikhail; Fang James; Ghali Jalal K; Martelet Michel; Wojciechowski Dariusz; Ansmite Baiba; Skards Janis; Laks Toivo; Henry David; Packer Milton; Pfeffer Marc A;
Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
American heart journal 2005;150(2):257-62.
2005: Stewart Simon; McMurray John J V; Hebborn Ansgar; Coats Andrew J S; Packer Milton;
Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom.
International journal of cardiology 2005;100(1):143-9.
2005: Maurer Mathew S; King Donald L; El-Khoury Rumbarger Lyna; Packer Milton; Burkhoff Daniel
Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms.
Journal of cardiac failure 2005;11(3):177-87.
2005: Packer Milton; McMurray John; Massie Barry M; Caspi Abraham; Charlon Vincent; Cohen-Solal Alain; Kiowski Wolfgang; Kostuk William; Krum Henry; Levine Barry; Rizzon Paolo; Soler Jordi; Swedberg Karl; Anderson Susan; Demets David L
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.
Journal of cardiac failure 2005;11(1):12-20.
2005: Stanton Eric B; Hansen Mark S; Sole Michael J; Gawad Yehia; Packer Milton; Pitt Bertram; Swedberg Karl; Rouleau Jean L;
Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure.
The Canadian journal of cardiology 2005;21(1):39-43.
2004: Tokmakova Mariya P; Skali Hicham; Kenchaiah Satish; Braunwald Eugene; Rouleau Jean L; Packer Milton; Chertow Glenn M; Moyé Lemuel A; Pfeffer Marc A; Solomon Scott D
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
Circulation 2004;110(24):3667-73.
2004: Packer Milton
Milton Packer, MD, Director, Center for Biostatistics and Clinical Science at UT Southwestern.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2004;52(7):421-4.
2004: Hartmann Franz; Packer Milton; Coats Andrew J S; Fowler Michael B; Krum Henry; Mohacsi Paul; Rouleau Jean L; Tendera Michal; Castaigne Alain; Anker Stefan D; Amann-Zalan Ildiko; Hoersch Silke; Katus Hugo A
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
Circulation 2004;110(13):1780-6.
2004: Maurer Mathew S; Packer Milton; Burkhoff Daniel
Diastolic heart failure.
The New England journal of medicine 2004;351(11):1143-5; author reply 1143-5.
2004: Majumdar Sumit R; McAlister Finlay A; Cree Marilyn; Chang Wei-Ching; Packer Milton; Armstrong Paul W;
Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
Clinical therapeutics 2004;26(5):694-703.
2004: Wu Alan H B; Packer Milton; Smith Andrew; Bijou Rachel; Fink Daniel; Mair Johannes; Wallentin Lars; Johnston Nina; Feldcamp Carolyn S; Haverstick Doris M; Ahnadi Charaf E; Grant Andrew; Despres Normand; Bluestein Barry; Ghani Farooq
Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study.
Clinical chemistry 2004;50(5):867-73.
2004: Massie Barry M; Krol William F; Ammon Susan E; Armstrong Paul W; Cleland John G; Collins Joseph F; Ezekowitz Michael; Jafri Syed M; O'Connor Christopher M; Packer Milton; Schulman Kevin A; Teo Koon; Warren Stuart
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics.
Journal of cardiac failure 2004;10(2):101-12.
2004: Konstam Marvin A; Lindenfeld Joann; Pina Ileana L; Packer Milton; Lazar Ronald M; Warner Stevenson Lynne;
Key issues in trial design for ventricular assist devices: a position statement of the Heart Failure Society of America.
Journal of cardiac failure 2004;10(2):91-100.
2004: Rouleau Jean L; Roecker Ellen B; Tendera Michal; Mohacsi Paul; Krum Henry; Katus Hugo A; Fowler Michael B; Coats Andrew J S; Castaigne Alain; Scherhag Armin; Holcslaw Terry L; Packer Milton;
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.
Journal of the American College of Cardiology 2004;43(8):1423-9.
2004: Mann Douglas L; McMurray John J V; Packer Milton; Swedberg Karl; Borer Jeffrey S; Colucci Wilson S; Djian Jacques; Drexler Helmut; Feldman Arthur; Kober Lars; Krum Henry; Liu Peter; Nieminen Markku; Tavazzi Luigi; van Veldhuisen Dirk Jan; Waldenstrom Anders; Warren Marshelle; Westheim Arne; Zannad Faiez; Fleming Thomas
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
Circulation 2004;109(13):1594-602.
2004: Hartmann Franz; Packer Milton; Coats Andrew J S; Fowler Michael B; Krum Henry; Mohacsi Paul; Rouleau Jean L; Tendera Michal; Castaigne Alain; Trawinski Jürgen; Amann-Zalan Ildiko; Hoersch Silke; Katus Hugo A
NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2004;6(3):343-50.
2004: DeMets David; Califf Robert; Dixon Dennis; Ellenberg Susan; Fleming Thomas; Held Peter; Julian Desmond; Kaplan Richard; Levine Robert; Neaton James; Packer Milton; Pocock Stuart; Rockhold Frank; Seto Belinda; Siegel Jay; Snapinn Steve; Stump David; Temple Robert; Whitley Richard
Issues in regulatory guidelines for data monitoring committees.
Clinical trials (London, England) 2004;1(2):162-9.
2003: Packer Milton
Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
Journal of cardiac failure 2003;9(6):429-43.
2003: Packer Milton
Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure?
Circulation 2003;108(24):2950-3.
2003: Chung Eugene S; Packer Milton; Lo Kim Hung; Fasanmade Adedigbo A; Willerson James T;
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.
Circulation 2003;107(25):3133-40.
2003: Konstam Marvin A; Pina Ileana; Lindenfeld Joann; Packer Milton
A device is not a drug.
Journal of cardiac failure 2003;9(3):155-7.
2003: Rouleau J L; Pitt B; Dhalla N S; Dhalla K S; Swedberg K; Hansen M S; Stanton E; Lapointe N; Packer M;
Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure.
American heart journal 2003;145(5):926-32.
2003: Krum Henry; Roecker Ellen B; Mohacsi Paul; Rouleau Jean L; Tendera Michal; Coats Andrew J S; Katus Hugo A; Fowler Michael B; Packer Milton;
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.
JAMA : the journal of the American Medical Association 2003;289(6):712-8.
2003: Burkhoff Daniel; Maurer Mathew S; Packer Milton
Heart failure with a normal ejection fraction: is it really a disorder of diastolic function?
Circulation 2003;107(5):656-8.
2003: Vittorio Timothy J; Lang Chim C; Katz Stuart D; Packer Milton; Mancini Donna M; Jorde Ulrich P
Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers.
Circulation 2003;107(2):290-3.
2002: Hansen Mark S; Stanton Eric B; Gawad Yehia; Packer Milton; Pitt Bertram; Swedberg Karl; Rouleau Jean L;
Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan.
The American journal of cardiology 2002;90(9):969-73.
2002: Packer Milton; Fowler Michael B; Roecker Ellen B; Coats Andrew J S; Katus Hugo A; Krum Henry; Mohacsi Paul; Rouleau Jean L; Tendera Michal; Staiger Christoph; Holcslaw Terry L; Amann-Zalan Ildiko; DeMets David L;
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Circulation 2002;106(17):2194-9.
2002: Packer Milton
The impossible task of developing a new treatment for heart failure.
Journal of cardiac failure 2002;8(4):193-6.
2002: Packer Milton; Califf Robert M; Konstam Marvin A; Krum Henry; McMurray John J; Rouleau Jean-Lucien; Swedberg Karl
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Circulation 2002;106(8):920-6.
2002: Neuberg Gerald W; Miller Alan B; O'Connor Chris M; Belkin Robert N; Carson Peter E; Cropp Anne B; Frid David J; Nye Regina G; Pressler Milton L; Wertheimer John H; Packer Milton;
Diuretic resistance predicts mortality in patients with advanced heart failure.
American heart journal 2002;144(1):31-8.
2002: Abraham William T; Fisher Westby G; Smith Andrew L; Delurgio David B; Leon Angel R; Loh Evan; Kocovic Dusan Z; Packer Milton; Clavell Alfredo L; Hayes David L; Ellestad Myrvin; Trupp Robin J; Underwood Jackie; Pickering Faith; Truex Cindy; McAtee Peggy; Messenger John;
Cardiac resynchronization in chronic heart failure.
The New England journal of medicine 2002;346(24):1845-53.
2002: Deng M C; Smits J M A; Packer M
Selecting patients for heart transplantation: which patients are too well for transplant?
Current opinion in cardiology 2002;17(2):137-44.
2002: Hunt Sharon A; Baker David W; Chin Marshall H; Cinquegrani Michael P; Feldman Arthur M; Francis Gary S; Ganiats Theodore G; Goldstein Sidney; Gregoratos Gabriel; Jessup Mariell L; Noble R Joseph; Packer Milton; Silver Marc A; Stevenson Lynne Warner; Gibbons Raymond J; Antman Elliott M; Alpert Joseph S; Faxon David P; Fuster Valentin; Gregoratos Gabriel; Jacobs Alice K; Hiratzka Loren F; Russell Richard O; Smith Sidney C;
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2002;21(2):189-203.
2001: Hunt S A; Baker D W; Chin M H; Cinquegrani M P; Feldman A M; Francis G S; Ganiats T G; Goldstein S; Gregoratos G; Jessup M L; Noble R J; Packer M; Silver M A; Stevenson L W; Gibbons R J; Antman E M; Alpert J S; Faxon D P; Fuster V; Gregoratos G; Jacobs A K; Hiratzka L F; Russell R O; Smith S C;
ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America.
Circulation 2001;104(24):2996-3007.
2001: Hunt S A; Baker D W; Chin M H; Cinquegrani M P; Feldman A M; Francis G S; Ganiats T G; Goldstein S; Gregoratos G; Jessup M L; Noble R J; Packer M; Silver M A; Stevenson L W; Gibbons R J; Antman E M; Alpert J S; Faxon D P; Fuster V; Jacobs A K; Hiratzka L F; Russell R O; Smith S C;
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).
Journal of the American College of Cardiology 2001;38(7):2101-13.
2001: Cleland J G; Thygesen K; Uretsky B F; Armstrong P; Horowitz J D; Massie B; Packer M; Poole-Wilson P A; Rydén L;
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study.
European heart journal 2001;22(17):1601-12.
2001: Packer M
Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure.
Journal of cardiac failure 2001;7(2):176-82.
2001: Packer M; Antonopoulos G V; Berlin J A; Chittams J; Konstam M A; Udelson J E
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.
American heart journal 2001;141(6):899-907.
2001: Packer M; Coats A J; Fowler M B; Katus H A; Krum H; Mohacsi P; Rouleau J L; Tendera M; Castaigne A; Roecker E B; Schultz M K; DeMets D L;
Effect of carvedilol on survival in severe chronic heart failure.
The New England journal of medicine 2001;344(22):1651-8.
2001: Fowler M B; Vera-Llonch M; Oster G; Bristow M R; Cohn J N; Colucci W S; Gilbert E M; Lukas M A; Lacey M J; Richner R; Young S T; Packer M
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.
Journal of the American College of Cardiology 2001;37(6):1692-9.
2001: Packer M
Current role of beta-adrenergic blockers in the management of chronic heart failure.
The American journal of medicine 2001;110 Suppl 7A():81S-94S.
2001: Yancy C W; Fowler M B; Colucci W S; Gilbert E M; Bristow M R; Cohn J N; Lukas M A; Young S T; Packer M;
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.
The New England journal of medicine 2001;344(18):1358-65.
2001: Massie B M; Armstrong P W; Cleland J G; Horowitz J D; Packer M; Poole-Wilson P A; Rydén L
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.
Archives of internal medicine 2001;161(2):165-71.
2000: Rydén L; Armstrong P W; Cleland J G; Horowitz J D; Massie B M; Packer M; Poole-Wilson P A
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
European heart journal 2000;21(23):1967-78.
2000: Carson P A; O'Connor C M; Miller A B; Anderson S; Belkin R; Neuberg G W; Wertheimer J H; Frid D; Cropp A; Packer M
Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial.
Journal of the American College of Cardiology 2000;36(2):541-6.
2000: Uretsky B F; Thygesen K; Armstrong P W; Cleland J G; Horowitz J D; Massie B M; Packer M; Poole-Wilson P A; Ryden L
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial.
Circulation 2000;102(6):611-6.
2000: Packer M
Dispelling the myth: incorporating beta-blockers into practice guidelines.
The American journal of managed care 2000;6(6 Suppl):S313-6.
2000: Moe G W; Rouleau J L; Charbonneau L; Proulx G; Arnold J M; Hall C; de Champlain J; Barr A; Sirois P; Packer M
Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
American heart journal 2000;139(4):587-95.
2000: Packer M
Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure.
American heart journal 2000;139(4):S202-6.
2000: Udelson J E; DeAbate C A; Berk M; Neuberg G; Packer M; Vijay N K; Gorwitt J; Smith W B; Kukin M L; LeJemtel T; Levine T B; Konstam M A
Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction.
American heart journal 2000;139(3):503-10.
2000: Teerlink J R; Jalaluddin M; Anderson S; Kukin M L; Eichhorn E J; Francis G; Packer M; Massie B M
Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators.
Circulation 2000;101(1):40-6.
1999: Packer M; Poole-Wilson P A; Armstrong P W; Cleland J G; Horowitz J D; Massie B M; Rydén L; Thygesen K; Uretsky B F
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.
Circulation 1999;100(23):2312-8.
1999: Packer M; Miller A B
Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure.
The American journal of cardiology 1999;84(4A):1L-2L.
1999: Packer M
Implications of the ATLAS study for clinical practice.
International journal of clinical practice. Supplement 1999;100():21-3.
1999: Cleland J G; Armstrong P; Horowitz J D; Massie B; Packer M; Poole-Wilson P A; Rydén L
Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 1999;1(1):73-9.
1999: Cleland J G; Massie B M; Packer M
Sudden death in heart failure: vascular or electrical?
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 1999;1(1):41-5.
1999: Rose E A; Moskowitz A J; Packer M; Sollano J A; Williams D L; Tierney A R; Heitjan D F; Meier P; Ascheim D D; Levitan R G; Weinberg A D; Stevenson L W; Shapiro P A; Lazar R M; Watson J T; Goldstein D J; Gelijns A C
The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure.
The Annals of thoracic surgery 1999;67(3):723-30.
1998: Lechat P; Packer M; Chalon S; Cucherat M; Arab T; Boissel J P
Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials.
Circulation 1998;98(12):1184-91.
1998: Packer M
Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice.
Progress in cardiovascular diseases 1998;41(1 Suppl 1):39-52.
1998: Massie B M; Cleland J G; Armstrong P W; Horowitz J D; Packer M; Poole-Wilson P A; Ryden L;
Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators.
Journal of cardiac failure 1998;4(1):3-8.
1998: Adams K F; Gheorghiade M; Uretsky B F; Young J B; Patterson J H; Tomasko L; Packer M
Clinical predictors of worsening heart failure during withdrawal from digoxin therapy.
American heart journal 1998;135(3):389-97.
1998: Packer M
Do beta-blockers prolong survival in chronic heart failure? A review of the experimental and clinical evidence.
European heart journal 1998;19 Suppl B():B40-6.
1998: Packer M
Beta-blockade in heart failure. Basic concepts and clinical results.
American journal of hypertension 1998;11(1 Pt 2):23S-37S.
1997: Packer M
Effects of beta-adrenergic blockade on survival of patients with chronic heart failure.
The American journal of cardiology 1997;80(11A):46L-54L.
1997: Wang J; Yi G H; Knecht M; Cai B L; Poposkis S; Packer M; Burkhoff D
Physical training alters the pathogenesis of pacing-induced heart failure through endothelium-mediated mechanisms in awake dogs.
Circulation 1997;96(8):2683-92.
1997: Goldsmith R L; Bigger J T; Bloomfield D M; Krum H; Steinman R C; Sackner-Bernstein J; Packer M
Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure.
The American journal of cardiology 1997;80(8):1101-4.
1997: Cohn J N; Fowler M B; Bristow M R; Colucci W S; Gilbert E M; Kinhal V; Krueger S K; Lejemtel T; Narahara K A; Packer M; Young S T; Holcslaw T L; Lukas M A
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.
Journal of cardiac failure 1997;3(3):173-9.
1997: Adams K F; Gheorghiade M; Uretsky B F; Young J B; Ahmed S; Tomasko L; Packer M
Patients with mild heart failure worsen during withdrawal from digoxin therapy.
Journal of the American College of Cardiology 1997;30(1):42-8.
1997: Todaka K; Wang J; Yi G H; Knecht M; Stennett R; Packer M; Burkhoff D
Impact of exercise training on ventricular properties in a canine model of congestive heart failure.
The American journal of physiology 1997;272(3 Pt 2):H1382-90.
1997: Packer M
End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis?
The New England journal of medicine 1997;336(8):575-6.
1997: Knecht M; Burkhoff D; Yi G H; Popilskis S; Homma S; Packer M; Wang J
Coronary endothelial dysfunction precedes heart failure and reduction of coronary reserve in awake dogs.
Journal of molecular and cellular cardiology 1997;29(1):217-27.
1997: Todaka K; Leibowitz D; Homma S; Fisher P E; Derosa C; Stennett R; Packer M; Burkhoff D
Characterizing ventricular mechanics and energetics following repeated coronary microembolization.
The American journal of physiology 1997;272(1 Pt 2):H186-94.
1996: Marcus L S; Hart D; Packer M; Yushak M; Medina N; Danziger R S; Heitjan D F; Katz S D
Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial.
Circulation 1996;94(12):3184-9.
1996: Colucci W S; Packer M; Bristow M R; Gilbert E M; Cohn J N; Fowler M B; Krueger S K; Hershberger R; Uretsky B F; Bowers J A; Sackner-Bernstein J D; Young S T; Holcslaw T L; Lukas M A
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.
Circulation 1996;94(11):2800-6.
1996: Packer M; Colucci W S; Sackner-Bernstein J D; Liang C S; Goldscher D A; Freeman I; Kukin M L; Kinhal V; Udelson J E; Klapholz M; Gottlieb S S; Pearle D; Cody R J; Gregory J J; Kantrowitz N E; LeJemtel T H; Young S T; Lukas M A; Shusterman N H
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.
Circulation 1996;94(11):2793-9.
1996: Packer M
Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?
Journal of the American College of Cardiology 1996;28(5):1323-7.
1996: Todaka K; Wang J; Yi G H; Stennett R; Knecht M; Packer M; Burkhoff D
Effects of levosimendan on myocardial contractility and oxygen consumption.
The Journal of pharmacology and experimental therapeutics 1996;279(1):120-7.
1996: Packer M; O'Connor C M; Ghali J K; Pressler M L; Carson P E; Belkin R N; Miller A B; Neuberg G W; Frid D; Wertheimer J H; Cropp A B; DeMets D L
Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.
The New England journal of medicine 1996;335(15):1107-14.
1996: Massie B M; Shah N B; Pitt B; Packer M
Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan.
American heart journal 1996;132(1 Pt 1):130-6.
1996: Packer M; Bristow M R; Cohn J N; Colucci W S; Fowler M B; Gilbert E M; Shusterman N H
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
The New England journal of medicine 1996;334(21):1349-55.
1996: Packer M
New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms.
Journal of internal medicine 1996;239(4):327-33.
1996: Packer M
Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease.
European heart journal 1996;17 Suppl B():21-3.
1996: Krum H; Gu A; Wilshire-Clement M; Sackner-Bernstein J; Goldsmith R; Medina N; Yushak M; Miller M; Packer M
Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure.
American heart journal 1996;131(2):337-41.
1995: Packer M
Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?
Circulation 1995;92(6):1379-82.
1995: Packer M
Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure.
European heart journal 1995;16 Suppl F():4-6.
1995: Krum H; Goldsmith R; Wilshire-Clement M; Miller M; Packer M
Role of endothelin in the exercise intolerance of chronic heart failure.
The American journal of cardiology 1995;75(17):1282-3.
1995: Levin H R; Oz M C; Chen J M; Packer M; Rose E A; Burkhoff D
Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading.
Circulation 1995;91(11):2717-20.
1995: Krum H; Bigger J T; Goldsmith R L; Packer M
Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure.
Journal of the American College of Cardiology 1995;25(2):289-94.
1995: Gilbert E M; Packer M
The use of placebo controls.
The New England journal of medicine 1995;332(1):61; author reply 62.
1995: Horn E M; Kukin M L; Neuberg G W; Goldsmith R L; McCarty M; Gratch M; Medina N; Yushak M; Packer M; Bilezikian J P
Lymphocyte G proteins reflect response to treatment in congestive heart failure.
American heart journal 1995;129(1):98-106.
1995: Packer M
A novel approach to the development of positive inotropic agents for chronic heart failure.
Journal of cardiovascular pharmacology 1995;26 Suppl 1():S52-6.
1994: Levin H R; Chen J M; Oz M C; Catanese K A; Krum H; Goldsmith R L; Packer M; Rose E A
Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation.
The Annals of thoracic surgery 1994;58(5):1515-20.
1994: Rutherford J D; Pfeffer M A; Moyé L A; Davis B R; Flaker G C; Kowey P R; Lamas G A; Miller H S; Packer M; Rouleau J L
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.
Circulation 1994;90(4):1731-8.
1994: Rouleau J L; Packer M; Moyé L; de Champlain J; Bichet D; Klein M; Rouleau J R; Sussex B; Arnold J M; Sestier F
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
Journal of the American College of Cardiology 1994;24(3):583-91.
1994: Hall C; Rouleau J L; Moyè L; de Champlain J; Bichet D; Klein M; Sussex B; Packer M; Rouleau J; Arnold M O
N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction.
Circulation 1994;89(5):1934-42.
1993: Gottlieb S S; Kukin M L; Penn J; Fisher M L; Cines M; Medina N; Yushak M; Taylor M; Packer M
Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
Journal of the American College of Cardiology 1993;22(4):963-7.
1993: Packer M
The development of positive inotropic agents for chronic heart failure: how have we gone astray?
Journal of the American College of Cardiology 1993;22(4 Suppl A):119A-126A.
1993: Garg R; Packer M; Pitt B; Yusuf S
Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine.
Journal of the American College of Cardiology 1993;22(4 Suppl A):3A-5A.
1993: Lipicky R J; Packer M
Role of surrogate end points in the evaluation of drugs for heart failure.
Journal of the American College of Cardiology 1993;22(4 Suppl A):179A-184A.
1993: Massie B M; Berk M R; Brozena S C; Elkayam U; Plehn J F; Kukin M L; Packer M; Murphy B E; Neuberg G W; Steingart R M
Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
Circulation 1993;88(2):492-501.
1993: Rouleau J L; de Champlain J; Klein M; Bichet D; Moyé L; Packer M; Dagenais G R; Sussex B; Arnold J M; Sestier F
Activation of neurohumoral systems in postinfarction left ventricular dysfunction.
Journal of the American College of Cardiology 1993;22(2):390-8.
1993: Packer M
The search for the ideal positive inotropic agent.
The New England journal of medicine 1993;329(3):201-2.
1993: Packer M; Narahara K A; Elkayam U; Sullivan J M; Pearle D L; Massie B M; Creager M A
Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study.
Journal of the American College of Cardiology 1993;22(1):65-72.
1993: Packer M; Gheorghiade M; Young J B; Costantini P J; Adams K F; Cody R J; Smith L K; Van Voorhees L; Gourley L A; Jolly M K
Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study.
The New England journal of medicine 1993;329(1):1-7.
1993: Gupta S K; Granneman G R; Packer M; Boger R S
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure.
Journal of cardiovascular pharmacology 1993;21(5):834-40.
1993: Packer M
How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease.
The American journal of cardiology 1993;71(9):3C-11C.
1993: Eichhorn E J; Tandon P K; DiBianco R; Timmis G C; Fenster P E; Shannon J; Packer M
Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study.
Journal of the American College of Cardiology 1993;21(3):634-40.
1993: Packer M
Calcium antagonists for congestive heart failure: evolving concepts in bridge building.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1993;7(1):95-6.
1992: Packer M
Treatment of chronic heart failure.
Lancet 1992;340(8811):92-5.
1992: Packer M
Pathophysiology of chronic heart failure.
Lancet 1992;340(8811):88-92.
1992: Packer M
The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.
Journal of the American College of Cardiology 1992;20(1):248-54.
1992: Packer M
Long-term strategies in the management of heart failure: looking beyond ventricular function and symptoms.
The American journal of cardiology 1992;69(18):150G-154G.
1992: Pitt B; Cohn J N; Francis G S; Kostis J B; Packer M; Pfeffer M A; Swedberg K; Yusuf S
The effect of treatment on survival in congestive heart failure.
Clinical cardiology 1992;15(5):323-9.
1992: Packer M
Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure.
Circulation 1992;85(1 Suppl):I50-6.
1991: Packer M; Carver J R; Rodeheffer R J; Ivanhoe R J; DiBianco R; Zeldis S M; Hendrix G H; Bommer W J; Elkayam U; Kukin M L
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
The New England journal of medicine 1991;325(21):1468-75.
1991: Rouleau J L; Moyé L A; de Champlain J; Klein M; Bichet D; Packer M; Dagenais G; Sussex B; Arnold J M; Sestier F
Activation of neurohumoral systems following acute myocardial infarction.
The American journal of cardiology 1991;68(14):80D-86D.
1991: Steingart R M; Packer M; Hamm P; Coglianese M E; Gersh B; Geltman E M; Sollano J; Katz S; Moyé L; Basta L L
Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators.
The New England journal of medicine 1991;325(4):226-30.
1991: Packer M; Kukin M L
Management of patients with heart failure and angina: do coexistent diseases alter the response to cardiovascular drugs?
Journal of the American College of Cardiology 1991;17(3):740-2.
1991: Haber H L; Leavy J A; Kessler P D; Kukin M L; Gottlieb S S; Packer M
The erythrocyte sedimentation rate in congestive heart failure.
The New England journal of medicine 1991;324(6):353-8.
1991: Neuberg G W; Kukin M L; Penn J; Medina N; Yushak M; Packer M
Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure.
The American journal of cardiology 1991;67(1):63-6.
1990: Packer M
The placebo effect in heart failure.
American heart journal 1990;120(6 Pt 2):1579-82.
1990: Packer M
Calcium channel blockers in chronic heart failure. The risks of "physiologically rational" therapy.
Circulation 1990;82(6):2254-7.
1990: Gottlieb S S; Baruch L; Kukin M L; Bernstein J L; Fisher M L; Packer M
Prognostic importance of the serum magnesium concentration in patients with congestive heart failure.
Journal of the American College of Cardiology 1990;16(4):827-31.
1990: Packer M
Are nitrates effective in the treatment of chronic heart failure? Antagonist's viewpoint.
The American journal of cardiology 1990;66(4):458-61.
1990: Packer M
Role of the sympathetic nervous system in chronic heart failure. A historical and philosophical perspective.
Circulation 1990;82(2 Suppl):I1-6.
1990: Packer M
Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure.
Circulation 1990;82(2 Suppl):I77-88.
1990: Levine B; Kalman J; Mayer L; Fillit H M; Packer M
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.
The New England journal of medicine 1990;323(4):236-41.
1990: Packer M
Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition.
European heart journal 1990;11 Suppl D():44-52.
1990: Packer M
Diastolic function as a target of therapeutic interventions in chronic heart failure.
European heart journal 1990;11 Suppl C():35-40.
1990: Packer M
Potential role of potassium as a determinant of morbidity and mortality in patients with systemic hypertension and congestive heart failure.
The American journal of cardiology 1990;65(10):45E-51E; discussion 52E.
1990: Packer M
Hormone-electrolyte interactions in congestive heart failure: lessons from a 4,000-year-old Sumerian tablet.
The American journal of cardiology 1990;65(10):1E-3E; discussion 22E-23E.
1990: Gottlieb S S; Kukin M L; Medina N; Yushak M; Packer M
Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure.
Circulation 1990;81(3):860-4.
1990: Packer M
Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure.
Circulation 1990;81(2 Suppl):III78-86.
1989: Packer M
Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure.
Circulation 1989;80(6 Suppl):IV59-67.
1989: Packer M
Second generation calcium channel blockers in the treatment of chronic heart failure: are they any better than their predecessors?
Journal of the American College of Cardiology 1989;14(5):1339-42.
1989: Gottlieb S S; Packer M
Deleterious hemodynamic effects of lidocaine in severe congestive heart failure.
American heart journal 1989;118(3):611-2.
1989: Gradman A; Deedwania P; Cody R; Massie B; Packer M; Pitt B; Goldstein S
Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group.
Journal of the American College of Cardiology 1989;14(3):564-70; discussion 571-2.
1989: Packer M; Kukin M L; Neuberg G W; Pinsky D J; Penn J; Abittan M H
The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1989;7(5):S33-6.
1989: Packer M
Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension?
Chest 1989;95(6):1173-5.
1989: Gottlieb S S; Kukin M L; Ahern D; Packer M
Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure.
Journal of the American College of Cardiology 1989;13(7):1534-9.
1989: Packer M
The clinical significance of nitrate tolerance in patients with chronic heart failure.
European heart journal 1989;10 Suppl A():20-5.
1989: Gottlieb S S; Kukin M L; Yushak M; Medina N; Packer M
Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure.
Annals of internal medicine 1989;110(7):505-9.
1989: Packer M
Drug therapy. Combined beta-adrenergic and calcium-entry blockade in angina pectoris.
The New England journal of medicine 1989;320(11):709-18.
1989: Packer M
Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.
The American journal of cardiology 1989;63(2):41A-45A.
1989: Packer M
Therapeutic options in the management of chronic heart failure. Is there a drug of first choice?
Circulation 1989;79(1):198-204.
1989: Packer M
Does digitalis work in chronic heart failure? The end of a 200-year-old controversy.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1989;2(6):743-6.
1989: Packer M
Identification of risk factors predisposing to the development of functional renal insufficiency during treatment with converting-enzyme inhibitors in chronic heart failure.
Cardiology 1989;76 Suppl 2():50-5.
1989: Packer M
Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists.
Journal of cardiovascular pharmacology 1989;14 Suppl 5():S38-43.
1988: Packer M
Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope.
Journal of the American College of Cardiology 1988;12(5):1299-317.
1988: Packer M
Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? II. Protagonist's viewpoint.
Journal of the American College of Cardiology 1988;12(2):562-6.
1988: Packer M
Symposium on therapeutic challenges in the management of congestive heart failure. Part I.
Journal of the American College of Cardiology 1988;12(1):262-4.
1988: Packer M
Clinical trials in congestive heart failure: why do studies report conflicting results?
Annals of internal medicine 1988;109(1):3-5.
1988: Kessler P D; Packer M; Medina N; Yushak M
Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
Journal of cardiovascular pharmacology 1988;12(1):6-11.
1988: Packer M
Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure.
Circulation 1988;77(6 Pt 2):I64-73.
1988: Packer M
Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure.
European heart journal 1988;9 Suppl H():105-8.
1988: Packer M
Neurohormonal interactions and adaptations in congestive heart failure.
Circulation 1988;77(4):721-30.
1988: Packer M
Modulation of functional capacity and survival in congestive heart failure. Effects of activation of the sympathetic nervous system.
Postgraduate medicine 1988;Spec No():96-103.
1987: Packer M; Lee W H; Medina N; Yushak M; Bernstein J L; Kessler P D
Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction.
Journal of the American College of Cardiology 1987;10(6):1303-11.
1987: Packer M; Lee W H; Kessler P D; Medina N; Yushak M; Gottlieb S S
Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure.
Journal of the American College of Cardiology 1987;10(4):837-44.
1987: Packer M; Lee W H; Kessler P D; Gottlieb S S; Medina N; Yushak M
Prevention and reversal of nitrate tolerance in patients with congestive heart failure.
The New England journal of medicine 1987;317(13):799-804.
1987: Packer M
Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1987;10(1 Suppl 1):66-73.
1987: Packer M
Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition.
The American journal of cardiology 1987;60(1):179-84.
1987: Packer M; Kessler P D; Lee W H
Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far.
Circulation 1987;75(6 Pt 2):V56-64.
1987: Packer M; Lee W H; Medina N; Yushak M; Kessler P D; Gottlieb S S
Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure.
The American journal of medicine 1987;82(6):1119-26.
1987: Packer M
Do vasodilators prolong life in heart failure?
The New England journal of medicine 1987;316(23):1471-3.
1987: Packer M
Prolonging life in patients with congestive heart failure: the next frontier. Introduction.
Circulation 1987;75(5 Pt 2):IV1-3.
1987: Packer M; Leier C V
Survival in congestive heart failure during treatment with drugs with positive inotropic actions.
Circulation 1987;75(5 Pt 2):IV55-63.
1987: Packer M; Lee W H; Kessler P D; Gottlieb S S; Bernstein J L; Kukin M L
Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure.
Circulation 1987;75(5 Pt 2):IV80-92.
1987: Packer M; Lee W H; Medina N; Yushak M; Kessler P D
Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure.
Annals of internal medicine 1987;106(3):346-54.
1987: Packer M; Gottlieb S S; Blum M A
Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with congestive heart failure.
The American journal of medicine 1987;82(3A):4-10.
1987: Packer M
How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men.
Journal of the American College of Cardiology 1987;9(2):433-8.
1987: Kessler P D; Packer M
Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure.
American heart journal 1987;113(1):137-43.
1987: Packer M
Converting-enzyme inhibition in the management of severe chronic congestive heart failure: physiologic concepts.
Journal of cardiovascular pharmacology 1987;10 Suppl 7():S83-7.
1987: Packer M; Lee W H; Kessler P D; Gottlieb S S
Can we expect vasodilator therapy to prolong life in patients with congestive heart failure?
Journal of cardiovascular pharmacology 1987;9 Suppl 2():S73-5.
1986: Packer M; Lee W H; Kessler P D
Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system.
Circulation 1986;74(4):766-74.
1986: Packer M; Lee W H; Yushak M; Medina N
Comparison of captopril and enalapril in patients with severe chronic heart failure.
The New England journal of medicine 1986;315(14):847-53.
1986: Packer M; Medina N; Yushak M
Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy.
The American journal of cardiology 1986;57(15):1323-7.
1986: Packer M; Lee W H; Medina N; Yushak M
Systemic vasoconstrictor effects of oxygen administration in obliterative pulmonary vascular disorders.
The American journal of cardiology 1986;57(10):853-8.
1986: Packer M; Gottlieb S S; Kessler P D
Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. Basis of a new physiologic approach to control of arrhythmia.
The American journal of medicine 1986;80(4A):23-9.
1986: Packer M; Medina N; Yushak M
Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure.
Journal of the American College of Cardiology 1986;7(3):671-80.
1986: Packer M; Medina N; Yushak M; Lee W H
Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure.
The American journal of cardiology 1986;57(4):260-7.
1986: Packer M; Lee W H
Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.
The American journal of cardiology 1986;57(4):347-8.
1986: Lee W H; Packer M
Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.
Circulation 1986;73(2):257-67.
1986: Packer M; Lee W H; Medina N; Yushak M
Influence of renal function on the hemodynamic and clinical responses to long-term captopril therapy in severe chronic heart failure.
Annals of internal medicine 1986;104(2):147-54.
1986: Packer M; Medina N; Yushak M
Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure.
The American journal of the medical sciences 1986;291(1):8-15.
1986: Packer M
The role of vasodilator therapy in the treatment of severe chronic heart failure.
Drugs 1986;32 Suppl 5():13-26.
1986: Packer M; Kessler P D; Gottlieb S S
Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management.
Postgraduate medical journal 1986;62 Suppl 1():179-82.
1985: Packer M
Does pulmonary vasoconstriction play an important role in patients with primary pulmonary hypertension? A skeptic's view of vasodilator therapy.
Chest 1985;88(4 Suppl):265S-268S.
1985: Packer M
Sudden unexpected death in patients with congestive heart failure: a second frontier.
Circulation 1985;72(4):681-5.
1985: Packer M; Medina N; Yushak M; Lee W H
Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients.
British heart journal 1985;54(3):298-304.
1985: Packer M; Lee W H; Medina N; Yushak M
Hemodynamic and clinical significance of the pulmonary vascular response to long-term captopril therapy in patients with severe chronic heart failure.
Journal of the American College of Cardiology 1985;6(3):635-45.
1985: Packer M
Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards.
Annals of internal medicine 1985;103(2):258-70.
1985: Packer M
Mechanisms of nitrate action in patients with severe left ventricular failure: conceptual problems with the theory of venosequestration.
American heart journal 1985;110(1 Pt 2):259-64.
1985: Packer M; Medina N; Yushak M; Lee W H
Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: results of a randomized crossover study.
American heart journal 1985;109(6):1293-9.
1985: Massie B; Bourassa M; DiBianco R; Hess M; Konstam M; Likoff M; Packer M
Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.
Circulation 1985;71(5):963-71.
1985: Packer M; Medina N; Yushak M
Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure.
Circulation 1985;71(4):761-6.
1985: Packer M
Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic.
International journal of cardiology 1985;7(2):111-20.
1985: Packer M
Therapeutic application of calcium-channel antagonists for pulmonary hypertension.
The American journal of cardiology 1985;55(3):196B-201B.
1984: Packer M; Medina N; Yushak M
Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.
Circulation 1984;70(6):1038-47.
1984: Packer M; Medina N; Yushak M
Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure.
The American journal of cardiology 1984;54(8):1025-9.
1984: Packer M; Medina N; Yushak M
Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease.
Journal of the American College of Cardiology 1984;4(5):890-901.
1984: Packer M; Medina N; Yushak M
Efficacy of captopril in low-renin congestive heart failure: importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders.
The American journal of cardiology 1984;54(7):771-7.
1984: Packer M; Medina N; Yushak M; Wiener I
Detrimental effects of verapamil in patients with primary pulmonary hypertension.
British heart journal 1984;52(1):106-11.
1984: Packer M
Conceptual dilemmas in the classification of vasodilator drugs for severe chronic heart failure. Advocacy of a pragmatic approach to the selection of a therapeutic agent.
The American journal of medicine 1984;76(6A):3-13.
1984: Packer M; Medina N; Yushak M
Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition.
Annals of internal medicine 1984;100(6):782-9.
1984: Goldman M E; Packer M; Horowitz S F; Meller J; Patterson R E; Kukin M; Teichholz L E; Gorlin R
Relation between exercise-induced changes in ejection fraction and systolic loading conditions at rest in aortic regurgitation.
Journal of the American College of Cardiology 1984;3(4):924-9.
1984: Packer M; Medina N; Yushak M
Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure.
Journal of the American College of Cardiology 1984;3(4):1035-43.
1984: Dzau V J; Packer M; Lilly L S; Swartz S L; Hollenberg N K; Williams G H
Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia.
The New England journal of medicine 1984;310(6):347-52.
1983: Packer M
Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism.
Journal of the American College of Cardiology 1983;2(5):841-52.
1983: Packer M; Medina N; Yushak M; Meller J
Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure.
Circulation 1983;68(4):803-12.
1983: Massie B M; Packer M; Hanlon J T; Combs D T
Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure.
Journal of the American College of Cardiology 1983;2(2):338-44.
1983: Packer M
New perspectives on therapeutic application of nitrates as vasodilator agents for severe chronic heart failure.
The American journal of medicine 1983;74(6B):61-72.
1983: Cohen M; Packer M; Gorlin R
Indications for left ventricular aneurysmectomy.
Circulation 1983;67(4):717-22.
1983: Packer M; Meller J; Medina N; Yushak M
Quantitative differences in the hemodynamic effects of captopril and nitroprusside in severe chronic heart failure.
The American journal of cardiology 1983;51(1):183-8.
1982: Packer M; Medina N; Yushak M
Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs.
American heart journal 1982;104(5 Pt 2):1215-23.
1982: Packer M; Leon M B; Bonow R O; Kieval J; Rosing D R; Subramanian V B
Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris.
The American journal of cardiology 1982;50(4):903-12.
1982: Singh B N; Chew C Y; Josephson M A; Packer M
Part I: pharmacologic and hemodynamic actions and interactions. Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamil.
The American journal of cardiology 1982;50(4):886-93.
1982: Packer M; Frishman W H
Verapamil therapy for stable and unstable angina pectoris: calcium channel antagonists in perspective.
The American journal of cardiology 1982;50(4):881-5.
1982: Packer M; Gorlin R; Meller J; Medina N
Central hemodynamic effects of dipyridamole in severe heart failure: comparison with hydralazine.
Clinical pharmacology and therapeutics 1982;32(1):54-61.
1982: Packer M
Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.
Drugs 1982;24(1):64-74.
1982: Packer M; Greenberg B; Massie B; Dash H
Deleterious effects of hydralazine in patients with pulmonary hypertension.
The New England journal of medicine 1982;306(22):1326-31.
1982: Packer M; Meller J; Medina N; Yushak M; Smith H; Holt J; Guererro J; Todd G D; McAllister R G; Gorlin R
Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man.
Circulation 1982;65(4):660-8.
1982: Packer M; Meller J; Medina N; Yushak M; Gorlin R
Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.
The New England journal of medicine 1982;306(2):57-62.
1982: Packer M; Le Jemtel T H
Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure.
Progress in cardiovascular diseases 1982;24(4):275-92.
1981: Packer M; Meller J; Medina N; Yushak M; Gorlin R
Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy.
The American journal of cardiology 1981;48(5):939-46.
1981: Packer M; Meller J; Medina N; Yushak M; Gorlin R
Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy.
Circulation 1981;64(3):506-14.
1981: Packer M; Meller J; Medina N; Yushak M
Sustained effectiveness of minoxidil in heart failure after development of tolerance to other vasodilator drugs.
The American journal of cardiology 1981;48(2):375-9.
1981: Urquhart J; Patterson R E; Packer M; Goldsmith S J; Horowitz S F; Litwak R; Gorlin R
Quantification of valve regurgitation by radionuclide angiography before and after valve replacement surgery.
The American journal of cardiology 1981;47(2):287-91.
1980: Packer M; Meller J; Medina N; Gorlin R; Herman M V
Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure.
The New England journal of medicine 1980;303(5):250-5.
1980: Packer M; Meller J; Medina N; Gorlin R; Herman M V
Hemodynamic evaluation of hydralazine dosage in refractory heart failure.
Clinical pharmacology and therapeutics 1980;27(3):337-46.
1980: Packer M; Meller J; Medina N; Gorlin R; Herman M V
Dose requirements of hydralazine in patients with severe chronic congestive heart failure.
The American journal of cardiology 1980;45(3):655-60.
1980: Packer M
Is there a drug of choice for vasodilator therapy in patients with refractory heart failure?
Chest 1980;77(1):7-9.
1979: Packer M; Meller J; Medina N; Gorlin R; Herman M V
Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure.
The New England journal of medicine 1979;301(22):1193-7.
1979: Packer M; Meller J; Gorlin R; Herman M V
Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure: evidence for a direct negative chronotropic effect of prazosin.
The American journal of cardiology 1979;44(2):310-7.
1979: Packer M; Meller J; Gorlin R; Herman M V
Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.
Circulation 1979;59(3):531-9.
1978: Packer M; Meller J
Oral vasodilator therapy for chronic heart failure: a plea for caution.
The American journal of cardiology 1978;42(4):686-9.

Sign-in to see more